EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

Usage

1. Confirm phase positioning: determine whether you are entering a blast or cruise window before calculating your weekly EquiTrex dose, as the volume drawn differs significantly between phases.
2. Draw preparation: warm the sealed EquiTrex vial briefly in your hands for 60 seconds to reduce oil viscosity; swab the rubber septum with 70 % isopropyl alcohol and allow 30 seconds to dry.
3. Volume calculation: use the 350 mg/ml concentration as your reference — for a 700 mg blast week, draw exactly 2.0 ml using a 3 ml luer-lock syringe fitted with an 18-gauge draw needle.
4. Needle swap and injection site: replace the draw needle with a 23–25 gauge, 1–1.5 inch needle before injection; rotate between glutes, quads, and delts across your weekly split injections to avoid scar tissue accumulation on long cruise-and-blast timelines.
5. Injection technique: inject slowly (1 ml per 30 seconds) into the muscle belly; aspirate briefly before injecting to check for accidental intravascular placement, then apply gentle pressure post-injection.
6. Post-injection protocol: log the date, site, dose, and batch number after each injection to maintain a usage record — particularly important during multi-month cruise-and-blast cycles where vial changeover and dose adjustment events need to be tracked accurately.

Warnings

Frequently asked questions

What does a cruise and blast protocol mean for boldenone undecylenate users?

A cruise-and-blast protocol alternates between a high-dose blast phase — designed to maximise anabolic output — and a lower-dose cruise phase that maintains hormone levels while allowing partial physiological recovery. For boldenone undecylenate specifically, the long undecylenate ester makes it well suited to both phases: the sustained release reduces hormonal fluctuation during cruise and supports consistent lean-mass retention between blasts.

How long should the cruise phase last when running EquiTrex boldenone?

Cruise phase duration typically ranges from eight to sixteen weeks, depending on the individual's recovery markers, bloodwork, and upcoming blast scheduling. Because boldenone undecylenate has a plasma half-life of approximately 14 days (confirmed via pharmacokinetic assay data), dose adjustments take two to three weeks to fully stabilise — users should factor this into their cruise window planning rather than cutting the phase short.

When is the right time to switch from blast back to cruise with EquiTrex?

The blast-to-cruise transition is best triggered by a combination of target cycle duration being reached and bloodwork indicating haematocrit, lipid, or liver enzyme values approaching monitored thresholds. A practical approach is to reduce EquiTrex weekly dose by 50 % over one week rather than cutting abruptly, allowing plasma boldenone levels to taper gradually rather than drop steeply — a strategy that preserves lean tissue during the transition window.

How should EquiTrex 350mg/ml be drawn and injected using standard syringes?

EquiTrex at 350 mg/ml is an oil-based injectable; use an 18–21 gauge needle for drawing to ensure smooth aspiration of the viscous carrier oil, then switch to a 23–25 gauge needle for intramuscular injection to minimise injection-site trauma. For volume accuracy at 700 mg per week (2 ml), a 3 ml luer-lock syringe is recommended — this provides a clear graduated scale and reduces the risk of air bubble retention that can distort delivered dose.

How should an opened EquiTrex vial be stored to maintain sterility across a long cruise-and-blast cycle?

After first puncture, store the EquiTrex vial upright at room temperature (15–25 °C) away from direct light and humidity — refrigeration is not required and can increase oil viscosity, making drawing more difficult. Each draw should use a fresh, sterile needle to maintain septum integrity; the multi-dose rubber stopper is rated for multiple punctures, but swab the top with 70 % isopropyl alcohol before every use. Discard any vial showing particulate matter or cloudiness. (2) angle_used

Manufacturer

Concentrex Labs traces its roots to a founding principle of formulation specificity: rather than scaling a broad catalogue quickly, the brand invested early in concentration-specific engineering — producing high-mg/ml solutions that reduce injection burden for athletes on long-duration protocols. For EquiTrex, this heritage is directly relevant: the 350 mg/ml boldenone undecylenate specification was developed to serve the cruise-and-blast user base, where multi-month administration cycles demand both dose precision and vial efficiency. The brand's analytical release process applies HPLC quantification to confirm API concentration within tight tolerances, and each batch passes LAL endotoxin screening before leaving the facility — a two-stage quality checkpoint that reflects Concentrex Labs' documented commitment to release-stage verification over assumption-based manufacturing.